NASDAQ · VKTX
Viking Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for VKTX has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Dec 2026 | $-1.02 | $-0.67 | $-1.48 | 9 |
| Mar 2027 | $-0.85 | $-0.62 | $-1.08 | 3 |
| Jun 2027 | $-0.79 | $-0.57 | $-1.00 | 3 |
| Sep 2027 | $-0.76 | $-0.52 | $-1.00 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · MarketBeat · The Motley Fool- Zacks · Oct 29, 11:52 AM EDTVKTX Q3 Earnings Miss Estimates Amid Rising Clinical ExpensesViking Therapeutics' Q3 loss widens as rising costs weigh on results, while its obesity drug candidate advances through phase III studies.
- Zacks · Oct 29, 10:21 AM EDTLLY Stock Jumps as Q3 Earnings Beat Estimates, 2026 Sales View RaisedLilly's Q3 earnings and sales beat estimates, driven by Mounjaro and Zepbound, as the company raises its 2026 revenue outlook to $91-$92 billion.
- Zacks · Oct 29, 9:00 AM EDTVKTX Q3 Earnings Call Highlights Obesity Pipeline ProgressViking Therapeutics advances its Phase III obesity trials, reports promising VK2735 maintenance data and strengthens its cash position despite widening losses.
- RTTNews · Oct 29, 2:57 AM EDTViking Therapeutics Reports Wider Q3 Loss As VK2735 Phase 3 Programs Advance(RTTNews) – Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company, announced its third-quarter financial results and provided an update on its clinical pipeline and other corporate developments.
- MarketBeat · Oct 29, 2:04 AM EDTViking Therapeutics Q3 Earnings Call Highlights3 Emerging Biotech Stocks With Significant Upside PotentialViking Therapeutics (NASDAQ:VKTX) reported a wider third-quarter loss as it increased spending on late-stage obesity programs, while advancing phase III studies of both injectable and oral versions of its lead candidate,
- The Motley Fool · Oct 29, 12:13 AM EDTViking (VKTX) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Fintel · Oct 28, 9:51 PM EDTViking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateViking Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical pipeline. The company reported a net loss of $183.2 million, or $1.55 per share, for the third quarter of 2026, compared to a net loss of
- Zacks · Oct 27, 7:53 AM EDTBuy, Sell or Hold LLY Stock? Key Factors to Watch Ahead of Q3 EarningsLilly heads into Q3 earnings with Mounjaro, Zepbound and new drugs fueling growth, but pricing pressure, rising costs and competition pose challenges.
- Zacks · Oct 26, 9:02 AM EDTShould You Buy Viking Therapeutics Stock Ahead of Q3 Results?VKTX is likely to report Q3 results Oct. 28 as investors await updates on VK2735's oral and injectable obesity programs and 2027 data readouts.
- Zacks · Oct 23, 4:45 PM EDTHere's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader MarketViking Therapeutics, Inc. (VKTX) concluded the recent trading session at $24.42, signifying a -5.48% move from its prior day's close.
- Zacks · Oct 22, 4:50 PM EDTViking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to KnowIn the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $25.76, denoting a -2.35% move from the preceding trading day.
- Zacks · Oct 22, 11:31 AM EDTNVO vs. VKTX: Which Obesity Stock Could Deliver Bigger Gains?Viking Therapeutics' late-stage obesity drug and promising weight-maintenance data could offer greater upside than Novo Nordisk, despite higher clinical and commercial risks.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Viking Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.